Market research
TGNA.F Transgene SA
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 211M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.68
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0005175080
- Market cap
- 211M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.68
About
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TGNA.F discussion.
5 years, 5 months ago
Transgene SA is currently in a long term uptrend where the price is trading 0.7% above its 200 day moving average.
From a valuation standpoint, the stock is 97.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 34.5.
Transgene SA's total revenue sank by 0.0% to $4M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 16.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Transgene SA gets an overall score of 3/5.